EP2780375

AMGEN
Application Number
EP12805432A
Filing Date
Nov 15, 2012
Status
Revoked
May 31, 2024
Grant Date
Sep 11, 2019
External Links
Slate, Register

Biblio Summary

The patent EP2780375B1 was granted on Sep 11, 2019 by Amgen The patent is currently Revoked.

The table below shows 8 patent oppositions filed on the patent at EPO, listing each opposing company and filing date. Tracking these filings indicates that the applicant is active in this industry, while opposing companies may be signaling their own interest in competing within the same space. These disputes are essential for insights into competitor actions, patent strategy and emerging technological trends.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

SANOFIJun 12, 2020ADMISSIBLE
JAMES POOLE LIMITEDJun 11, 2020ADMISSIBLE
MATHYS & SQUIRE LLPJun 11, 2020ADMISSIBLE
REGENERON PHARMACEUTICALS, INC.Jun 11, 2020ADMISSIBLE
TENEOBIO, INC.Jun 10, 2020WITHDRAWN
PFIZER INC.May 4, 2020WITHDRAWN
JANSSEN BIOTECH, INC.Apr 14, 2020ADMISSIBLE
ABBVIE INC.Mar 6, 2020ADMISSIBLE

The table below shows the patents of Amgen that have been opposed by other companies.

Patent NumberTitleGrant DateOpposition Count
EP4209499Charged Depth Filtration Of Antigen-Binding ProteinsAug 7, 20241
EP3819007Dosing Regimen For Anti-Bcma AgentsJul 10, 20244
EP2637670Prevention Of Adverse Effects Caused By Cd3 Specific Binding DomainsMar 13, 20244